Evidence map›Paper›PMID 40510678›Full record

ArticleInternational journal of cardiology. Cardiovascular risk and prevention2025

Trends and disparities in inflammatory bowel disease and cardiovascular disease-related mortality in the United States from 1999 to 2023: A CDC WONDER analysis.

Syed Anjum Gardezi, Nakul Sachdeva, Insiya Mohammed Rampurawala, Akalanka Ranasinghe, Muhammad Umair Shehzad, Kieran Gill, Raheel Qureshi, Ashish Gupta, Ali Hasan, Muzammil Farhan and 4 more

Abstract read
In one paragraph

Article in International journal of cardiology. Cardiovascular risk and prevention, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. The hidden burden: Inflammatory bowel disease and cardiovascular mortality in underreported populations.International journal of cardiology. Cardiovascular risk and prevention · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Syed Anjum GardeziJohns Hopkins Healthcare Aramco, Eastern Province, Saudi Arabia.
Nakul SachdevaDepartment of Medicine, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, UK.
Insiya Mohammed RampurawalaDepartment of Medicine, Jagadguru Sri Shivarathreeshwara Medical College (JSSMC), Mysore, India.
Akalanka RanasingheDepartment of Cardiology, Queen Elizabeth Hospital Birmingham, Birmingham, UK.
Muhammad Umair ShehzadDiabetes and Endocrinology, Western General Hospital, Edinburgh, UK.
Kieran GillTranslational and Clinical Research Institute, Newcastle University Newcastle-upon-Tyne, UK.
Raheel QureshiQueen Elizabeth Hospital, Gateshead, UK.
Ashish GuptaSunderland Royal Hospital, UK.
Ali HasanDepartment of Medicine, Imperial College, London, UK.
Muzammil FarhanDepartment of Medicine, Imperial College, London, UK.
Azeem HassanDepartment of Medicine, Imperial College, London, UK.
Eeshal ZulfiqarDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Mushood AhmedDepartment of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan.
Raheel AhmedNational Heart & Lung Institute, Imperial College London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Individuals with inflammatory Bowel Disease (IBD) may face an increased risk of cardiovascular disease (CVD) due to chronic systemic inflammation and vascular dysfunction. While advancements in treatment have improved IBD management, its impact on cardiovascular mortality remains unclear. This study aims to analyze trends in IBD- and CVD-related mortality in the U.S. from 1999 to 2023, identifying high-risk populations based on age, sex, race, and geography. Methods: Mortality data for individuals aged 25 years and older from 1999 to 2023 were obtained from the CDC WONDER database. Crude mortality rates (CMRs) and age-adjusted mortality rates (AAMRs) per 100,000 persons were calculated. Temporal trends were assessed using Joinpoint regression analysis to estimate the annual percent change (APC) and average annual percent change (AAPC) in mortality rates. Results: Between 1999 and 2023, a total of 41,635 deaths were identified related to IBD and CVD among adults aged 25 years and older. The overall AAMR remained relatively stable from 1999 to 2018 before increasing sharply from 0.67 in 2018 to 1.03 in 2021 [APC: 15.63∗ (95 % CI: 11.66, 17.91); p = 0.0004], after which it plateaued through 2023. Males consistently exhibited higher AAMRs than females throughout the study period (Males: 1.10 vs. Females: 0.90 in 2023). When stratified by race, the highest AAMR was observed in NH White populations, followed by NH Black or African American individuals (1.21 vs. 0.64 in 2023). Regionally, the highest mortality was observed in the West, followed by the Midwest, the Northeast, and lastly, the South (AAMR of 1.02, 1.08, 0.87, and 0.97, respectively, in 2023). Rural areas (0.74) exhibited consistently higher AAMRs than urban areas (0.69) from 1999 to 2020. Mortality rates increased with age, with the highest burden observed in individuals aged 85 years and older. Conclusion: IBD- and CVD-related mortality has risen in the U.S., with the highest burden among males, NH White individuals, and older adults. Targeted interventions and enhanced cardiovascular screening are needed to reduce mortality in high-risk populations.

Indexed as

Cardiovascular diseaseCDC WONDERInflammatory bowel diseaseMortality

Identifiers

PMID40510678
PMCPMC12159954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.